NCT07881770Not yet recruiting
Semaglutide Health Outcomes and Patient Adherence in Australia
Semaglutide Health Outcomes and Patient Adherence on Digital Health Platforms in Australia (SHAPED-AU)
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia. The study will evaluate treatment patterns, adherence, quality of life, safety, and other health outcomes associated with semaglutide use in routine clinical practice. Information will be collected from data generated during standard clinical care, and no study-specific treatment or procedures will be required.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 13 Oct 2026
- Primary completion date
- 28 Feb 2028
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07881770
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 13 Oct 2026 to the primary completion date, 28 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous reported use of GLP-1 RA in the 3-month period before index date.
- Are currently taking another obesity medication i.e. medication indicated for weight management treatment.
- Any prior irreversible bariatric surgery for weight management
Other
- Presence of a documented refusal to participate in research.
Who the study is looking for
- Willing and able to provide informed consent
- Greater than or equal to (\>=) 18 years of age at time of informed consent
- Body Mass Index (BMI) \>= 27 kg/m2 and have \>= 1 excess weight-related comorbidity OR BMI \>= 30 kg/m2
- Eligible to be prescribed semaglutide for the management of overweight or obesity
- Have provided at least one weight measurement within 30 days of index date
- Enrolled in existing Eucalyptus DWLS programme.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.